BIOMAT Database Logo BIOMAT Database Logo

Immune rejection of tumor cells: in vivo significance of anti-tumor in vitro immune reactions. 1975

J P Levy, and J C Leclerc

The mechanism of immune tumor rejection remains poorly understood. The respective roles of antibodies, macrophages, cytolytic T cells (CTL) and that of "K" cells or any other cell which could be involved in antibody dependant cell mediated cytotoxicity are still unknown. It is probable that the CTL play some role in tumor rejection but the "in vivo" relevance of the other, "in vitro" detected phenomena, is less clear. The correlations between "in vivo" tumor rejection and "in vitro" detected reactions are very difficult to establish, specially for the following two reasons: a) the different methods used in vitro do not explore identical phenomena ; b) some of them provide both specific and non-specific reactions.

UI MeSH Term Description Entries
D008264 Macrophages The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.) Bone Marrow-Derived Macrophages,Monocyte-Derived Macrophages,Macrophage,Macrophages, Monocyte-Derived,Bone Marrow Derived Macrophages,Bone Marrow-Derived Macrophage,Macrophage, Bone Marrow-Derived,Macrophage, Monocyte-Derived,Macrophages, Bone Marrow-Derived,Macrophages, Monocyte Derived,Monocyte Derived Macrophages,Monocyte-Derived Macrophage
D009368 Neoplasm Transplantation Experimental transplantation of neoplasms in laboratory animals for research purposes. Transplantation, Neoplasm,Neoplasm Transplantations,Transplantations, Neoplasm
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D009374 Neoplasms, Experimental Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. Experimental Neoplasms,Experimental Neoplasm,Neoplasm, Experimental
D003601 Cytotoxicity Tests, Immunologic The demonstration of the cytotoxic effect on a target cell of a lymphocyte, a mediator released by a sensitized lymphocyte, an antibody, or complement. AHG-CDC Tests,Anti-Human Globulin Complement-Dependent Cytotoxicity Tests,Microcytotoxicity Tests,Anti Human Globulin Complement Dependent Cytotoxicity Tests,Anti-Human Globulin Complement-Dependent Cytotoxicity Test,Antiglobulin-Augmented Lymphocytotoxicity Test,Antiglobulin-Augmented Lymphocytotoxicity Tests,Cytotoxicity Test, Immunologic,Cytotoxicity Tests, Anti-Human Globulin Complement-Dependent,Cytotoxicity Tests, Immunological,Immunologic Cytotoxicity Test,Immunologic Cytotoxicity Tests,Lymphocytotoxicity Test, Antiglobulin-Augmented,Lymphocytotoxicity Tests, Antiglobulin-Augmented,Microcytotoxicity Test,AHG CDC Tests,AHG-CDC Test,Anti Human Globulin Complement Dependent Cytotoxicity Test,Antiglobulin Augmented Lymphocytotoxicity Test,Antiglobulin Augmented Lymphocytotoxicity Tests,Cytotoxicity Test, Immunological,Cytotoxicity Tests, Anti Human Globulin Complement Dependent,Immunological Cytotoxicity Test,Immunological Cytotoxicity Tests,Lymphocytotoxicity Test, Antiglobulin Augmented,Lymphocytotoxicity Tests, Antiglobulin Augmented
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000375 Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time. Senescence,Aging, Biological,Biological Aging
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000917 Antibody Formation The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS. Antibody Production,Antibody Response,Antibody Responses,Formation, Antibody,Production, Antibody,Response, Antibody,Responses, Antibody

Related Publications

J P Levy, and J C Leclerc
[Significance of thrombocytic immune reactions in vivo and in vitro].
January 1971, Bibliotheca haematologica,
J P Levy, and J C Leclerc
Tumor cells expressing a retroviral envelope escape immune rejection in vivo.
December 1998, Proceedings of the National Academy of Sciences of the United States of America,
J P Levy, and J C Leclerc
Rejection of tumor cells in vitro.
June 1973, Science (New York, N.Y.),
J P Levy, and J C Leclerc
Specificity of in vivo tumor rejection assessed by mixing immune spleen cells with target and unrelated tumor cells.
December 1973, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
J P Levy, and J C Leclerc
Effect of cyclophosphamide and methylprednisolone on in vitro cellular immune response to allogeneic tumor cells. Correlation with in vivo rejection.
September 1978, Transplantation,
J P Levy, and J C Leclerc
Artemisinin enhances the anti-tumor immune response in 4T1 breast cancer cells in vitro and in vivo.
May 2019, International immunopharmacology,
J P Levy, and J C Leclerc
Dendritic cells transfected with PEG10 recombinant adenovirus elicit anti-tumor immune response in vitro and in vivo.
April 2011, Vaccine,
J P Levy, and J C Leclerc
Visualizing anti-tumor immune responses in vivo.
January 2009, Disease models & mechanisms,
J P Levy, and J C Leclerc
Anti-tumor effect of AZD8055 against neuroblastoma cells in vitro and in vivo.
April 2018, Experimental cell research,
J P Levy, and J C Leclerc
Specific anti-tumor responses by cultured immune spleen cells. II. Culture supernatants induce specific anti-tumor cytotoxicity by non-immune lymphoid cells in vitro.
August 1975, International journal of cancer,
Copied contents to your clipboard!